Lowest Price Guaranteed
Slides
117
Last Updated
September 2026
View Count
25368
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis
6. INTRODUCTION
6.1. Chapter Overview
6.2. Classification of Vectors
6.2.1. Viral Vectors
6.2.1.1. Retrovirus Vectors
6.2.1.2. Lentivirus Vectors
6.2.1.3. Adeno-associated Viral Vectors
6.2.1.4. Adenovirus Vectors
6.2.1.5. Other Viral Vectors
6.2.1.5.1. Alphavirus
6.2.1.5.2. Foamy Virus
6.2.1.5.3. Simian Virus
6.2.1.5.4. Vaccinia Virus
6.2.1.5.5. Chimeric Viral Vectors
6.2.1.5.6. Herpes Simplex Virus
6.2.1.5.7. Sendai Virus
6.2.2. Non-Viral Vectors
6.3. Adeno-associated Viral Vectors
6.3.1. Structure and Design
6.3.2. Adeno-associated Viral Vector Life Cycle
6.3.3. Application of Adeno-associated Viral Vectors
6.3.3.1. Gene Therapy
6.3.3.2. Vaccination
6.3.4. Advantages of Adeno-associated Viral Vectors
6.3.5. Challenges Related to Adeno-associated Viral Vectors
6.4. Concluding Remarks
7. ADENO-ASSOCIATED VIRAL VECTOR BASED THERAPIES: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Adeno-associated Viral Vector Based Therapies: Overall Market Landscape
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Gene / Molecule Targeted
7.2.3. Analysis by Type of Therapy
7.2.4. Analysis by Route of Administration
7.2.5. Analysis by Therapeutic Area
7.2.6. Analysis by Special Designation Awarded
7.2.7. Analysis by Dose Frequency
7.3. Adeno-associated Viral Vector Based Therapy Developers: Overall Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters (Region)
7.3.4. Most Active Developers: Analysis by Number of Therapies Developed
8. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURERS: MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Adeno-associated Viral Vector Manufacturers: Overall Market Landscape
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size
8.2.3. Analysis by Location of Headquarters
8.2.4. Analysis by Type of Product Manufactured
8.2.5. Analysis by Type of Vector Manufactured
8.2.6. Analysis by Scale of Operation
8.2.7. Analysis by Type of Manufacturer
8.2.8. Analysis by Application Area
8.2.9. Analysis by Location of Vector Manufacturing Facility
9. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURING: TECHNOLOGIES / PLATFORMS LANDSCAPE
9.1. Chapter Overview
9.2. Adeno-associated Viral Vector Manufacturing: Technologies / Platforms Landscape
9.2.1. Analysis by Type of Vector Manufactured
9.2.2. Analysis by Type of Viral Vector Manufactured
9.2.3. Analysis by Scale of Operation
9.2.4. Analysis by End-use
9.3. Adeno-associated Viral Vector Manufacturing: Technology / Platform Providers Landscape
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
9.3.4. Most Active Players: Analysis by Number of Technologies / Platforms
10. COMPANY COMPETITIVENESS ANALYSIS: ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURERS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. Overview of Peer Groups
10.5. Company Competitiveness Analysis
10.5.1. Adeno-associated Viral Vector Manufacturers Headquartered in North America
10.5.2. Adeno-associated Viral Vector Manufacturers Headquartered in Europe
10.5.3. Adeno-associated Viral Vector Manufacturers Headquartered in Asia-Pacific and the Rest of the World
11. TECHNOLOGY COMPETITIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology
11.4. Overview of Peer Groups
11.5. Adeno-associated Viral Vector Technologies / Platforms: Competitiveness Analysis
11.5.1. Adeno-associated Viral Vector Technologies / Platforms Provided by Companies Headquartered in North America
11.5.2. Adeno-associated Viral Vector Technologies / Platforms Provided by Companies Headquartered in Europe and Asia-Pacific
12. MARKETED DRUG PROFILES
12.1. Chapter Overview
12.2. Elevidys (Developed by Sarepta Therapeutics)
12.2.1. Company Overview
12.2.2. Development Timeline
12.2.3. Mechanism of Action and Vector Used
12.2.4. Manufacturing, Dosage and Sales
12.2.5. Target Indication
12.2.6. Current Status of Development
12.3. Hemgenix (Developed by uniQure)
12.3.1. Company Overview
12.3.2. Development Timeline
12.3.3. Mechanism of Action and Vector Used
12.3.4. Manufacturing, Dosage and Sales
12.3.5. Target Indication
12.3.6. Current Status of Development
12.4. Kebilidi (Developed by PTC Therapeutics)
12.4.1. Company Overview
12.4.2. Development Timeline
12.4.3. Mechanism of Action and Vector Used
12.4.4. Manufacturing, Dosage and Sales
12.4.5. Target Indication
12.4.6. Current Status of Development
12.5. Luxturna (Developed by Spark Therapeutics)
12.5.1. Company Overview
12.5.2. Development Timeline
12.5.3. Mechanism of Action and Vector Used
12.5.4. Manufacturing, Dosage and Sales
12.5.5. Target Indication
12.5.6. Current Status of Development
12.6. Roctavian (Developed by Biomarin Pharmaceutical)
12.6.1. Company Overview
12.6.2. Development Timeline
12.6.3. Mechanism of Action and Vector Used
12.6.4. Manufacturing, Dosage and Sales
12.6.5. Target Indication
12.6.6. Current Status of Development
12.7. Zolgensma (Developed by Novartis)
12.7.1. Company Overview
12.7.2. Development Timeline
12.7.3. Mechanism of Action and Vector Used
12.7.4. Manufacturing, Dosage and Sales
12.7.5. Target Indication
12.7.6. Current Status of Development
12.8. Itvisma (Developed by Novartis)
12.8.1. Company Overview
12.8.2. Development Timeline
12.8.3. Mechanism of Action and Vector Used
12.8.4. Manufacturing, Dosage and Sales
12.8.5. Target Indication
12.8.6. Current Status of Development
12.9. BBM-H901 (Developed by Belief Biomed)
12.9.1. Company Overview
12.9.2. Development Timeline
12.9.3. Mechanism of Action and Vector Used
12.9.4. Manufacturing, Dosage and Sales
12.9.5. Target Indication
12.9.6. Current Status of Development
13. COMPANY PROFILES: LEADING ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURERS
13.1. Chapter Overview
13.2. Astellas Pharma
13.2.1. Company Overview
13.2.2. Vector Manufacturing Portfolio
13.3. Charles River Laboratories
13.3.1. Company Overview
13.3.2. Vector Manufacturing Portfolio
13.4. Cytiva
13.4.1. Company Overview
13.4.2. Vector Manufacturing Portfolio
13.5. Lonza
13.5.1. Company Overview
13.5.2. Vector Manufacturing Portfolio
13.6. Sanofi
13.6.1. Company Overview
13.6.2. Vector Manufacturing Portfolio
13.7. Thermo Fisher Scientific
13.7.1. Company Overview
13.7.2. Vector Manufacturing Portfolio
13.8. WuXi AppTec
13.8.1. Company Overview
13.8.2. Vector Manufacturing Portfolio
14. CLINICAL TRIAL ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Adeno-associated Viral Vector Based Therapies: Clinical Trial Analysis
14.3.1. Analysis by Trial Registration Year
14.3.2. Analysis of Patients Enrolled by Trial Registration Year
14.3.3. Analysis by Trial Phase
14.3.4. Analysis of Patients Enrolled by Trial Phase
14.3.5. Analysis by Trial Status
14.3.6. Analysis of Patients Enrolled by Trial Status
14.3.7. Analysis by Target Patient Population
14.3.8. Analysis by Patient Gender
14.3.9. Analysis by Type of Sponsor / Collaborator
14.3.10. Analysis by Study Design
14.3.10.1. Analysis by Type of Patient Allocation Model Used
14.3.10.2. Analysis by Type of Trial Masking Adopted
14.3.10.3. Analysis by Type of Trial Intervention Model
14.3.10.4. Analysis by Trial Purpose
14.3.11. Most Active Players: Analysis by Number of Clinical Trials Sponsored / Collaborated
14.3.12. Analysis by Geography
14.3.12.1. Analysis of Clinical Trials by Geography
14.3.12.2. Analysis of Clinical Trials by Geography and Trial Status
14.3.12.3. Analysis of Patients Enrolled by Geography and Trial Status
14.3.12.4. Analysis of Clinical Trials by Geography, Trial Status and Trial Phase
15. PARTNERSHIPS AND COLLABORATIONS: ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURERS
15.1. Chapter Overview
15.2. Partnership Models
15.3. Adeno-associated Viral Vector Manufacturers: Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Year and Type of Partnership
15.3.4. Analysis by Type of Partner
15.3.5. Analysis by Scale of Operation
15.3.6. Analysis by Therapeutic Area
15.3.7. Analysis by Application Area
15.3.8. Most Active Players: Analysis by Number of Partnerships
15.4. Analysis by Geography
15.4.1. Analysis by Local and International Agreements
15.4.2. Analysis by Intracontinental and Intercontinental Agreements
16. PARTNERSHIPS AND COLLABORATIONS: ADENO-ASSOCIATED VIRAL VECTOR THERAPY DEVELOPERS
16.1. Adeno-associated Viral Vector Therapy Developers: Partnerships and Collaborations
16.2. Partnership Models
16.2.1. Analysis by Year of Partnership
16.2.2. Analysis by Type of Partnership
16.2.3. Analysis by Year and Type of Partnership
16.2.4. Analysis by Type of Partner
16.2.5. Analysis by Therapeutic Area
16.2.6. Most Active Players: Analysis by Number of Partnerships
16.3. Analysis by Geography
16.3.1. Intercontinental and Intracontinental Agreements
16.3.2. Local and International Agreements
17. PATENT ANALYSIS
17.1. Chapter Overview
17.2. Scope and Methodology
17.3. Adeno-associated Viral Vector Market: Patent Analysis
17.3.1. Analysis by Patent Application Year
17.3.2. Analysis by Patent Publication Year
17.3.3. Analysis by Type of Patent and Publication Year
17.3.4. Analysis by Patent Jurisdiction
17.3.5. Analysis by CPC Symbols
17.3.6. Analysis by Type of Applicant
17.3.7. Leading Industry Players: Analysis by Number of Patents
17.3.8. Leading Non-Industry Players: Analysis by Number of Patents
17.3.9. Leading Patent Assignees: Analysis by Number of Patents
17.4. Patent Benchmarking Analysis
17.4.1. Analysis by Patent Characteristics
17.5. Patent Valuation
17.6. Leading Patents by Number of Citations
18. START-UP HEALTH INDEXING
18.1. Chapter Overview
18.2. Start-ups Developing Adeno-associated Viral Vector Based Therapies
18.2.1. Analysis by Location of Headquarters
18.3. Benchmarking of Start-ups
18.3.1. Analysis by Pipeline Strength
18.3.2. Analysis by Pipeline Maturity
18.3.3. Analysis by Indication Diversity
18.3.4. Analysis by Patent Strength
18.3.5. Analysis by Partnership Activity
18.3.6. Start-ups Health Indexing: Roots Analysis Perspective
19. OUTSOURCING: GO / NO-GO FRAMEWORK
19.1. Chapter Overview
19.2. Outsourcing: Go / No-Go Framework
19.3. Adeno-associated Viral Vector Developers Outsourcing: Go / No-Go Framework
19.3.1. Key Assumptions and Parameters
19.3.2. Methodology
19.3.3. Results and Interpretations
19.3.3.1. Adeno-associated Viral Vector Based Therapy Developers: Benchmarking of Small Companies
19.3.3.2. Adeno-associated Viral Vector Based Therapy Developers: Benchmarking of Mid-sized Companies
19.3.3.3. Adeno-associated Viral Vector Based Therapy Developers: Benchmarking of Large Companies
19.4. Concluding Remarks
20. MARKET IMPACT ANALYSIS
20.1. Chapter Overview
20.2. Market Drivers
20.3. Market Restraints
20.4. Market Opportunities
20.5. Market Challenges
20.6. Conclusion
21. GLOBAL ADENO-ASSOCIATED VIRAL VECTOR BASED THERAPIES MARKET
21.1. Chapter Overview
21.2. Assumptions and Methodology
21.3. Global Adeno-associated Viral Vector Based Therapies Market: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
21.3.1. Scenario Analysis
21.3.1.1. Conservative Scenario
21.3.1.2. Optimistic Scenario
21.4. Key Market Segmentations
22. ADENO-ASSOCIATED VIRAL VECTOR BASED THERAPIES MARKET, BY TYPE OF THERAPY
22.1. Chapter Overview
22.2. Assumptions and Methodology
22.3. Adeno-associated Viral Vector Based Therapies Market: Distribution by Type of Therapy
22.3.1. Adeno-associated Viral Vector Based Therapies Market for Gene Augmentation Therapies: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
22.3.2. Adeno-associated Viral Vector Based Therapies Market for Gene Regulation Therapies: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
22.3.3. Adeno-associated Viral Vector Based Therapies Market for Gene Editing Therapies: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
22.4. Data Triangulation and Validation
23. ADENO-ASSOCIATED VIRAL VECTOR BASED THERAPIES MARKET, BY THERAPEUTIC AREA
23.1. Chapter Overview
23.2. Assumptions and Methodology
23.3. Adeno-associated Viral Vector Based Therapies Market: Distribution by Therapeutic Area
23.3.1. Adeno-associated Viral Vector Based Therapies Market for Ophthalmic Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.3.2. Adeno-associated Viral Vector Based Therapies Market for Hematological Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.3.3. Adeno-associated Viral Vector Based Therapies Market for Musculoskeletal Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.3.4. Adeno-associated Viral Vector Based Therapies Market for Metabolic Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.4. Data Triangulation and Validation
24. ADENO-ASSOCIATED VIRAL VECTOR BASED THERAPIES MARKET, BY GEOGRAPHICAL REGIONS
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Adeno-associated Viral Vector Based Therapies Market: Distribution by Geographical Regions
24.3.1. Adeno-associated Viral Vector Based Therapies Market in North America: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.2. Adeno-associated Viral Vector Based Therapies Market in Europe: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.3. Adeno-associated Viral Vector Based Therapies Market in Asia-Pacific and Rest of the World: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.4. Market Dynamics Assessment
24.4.1. Penetration Growth (P-G) Matrix
24.5. Data Triangulation and Validation
25. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA
25.1. Adeno-associated Viral Vector Based Therapies Market in North America: Distribution by Type of Therapy
25.1.1. Adeno-associated Viral Vector Based Therapies Market in North America for Gene Augmentation Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.1.2. Adeno-associated Viral Vector Based Therapies Market in North America for Gene Regulation Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.1.3. Adeno-associated Viral Vector Based Therapies Market in North America for Gene Editing Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.2. Adeno-associated Viral Vector Based Therapies Market in North America: Distribution by Therapeutic Area
25.2.1. Adeno-associated Viral Vector Based Therapies Market in North America for Ophthalmic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.2.2. Adeno-associated Viral Vector Based Therapies Market in North America for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.2.3. Adeno-associated Viral Vector Based Therapies Market in North America for Musculoskeletal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.2.4. Adeno-associated Viral Vector Based Therapies Market in North America for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26. MARKET OPPORTUNITY ANALYSIS: EUROPE
26.1. Adeno-associated Viral Vector Based Therapies Market in Europe: Distribution by Type of Therapy
26.1.1. Adeno-associated Viral Vector Based Therapies Market in Europe for Gene Augmentation Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.1.2. Adeno-associated Viral Vector Based Therapies Market in Europe for Gene Regulation Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.1.3. Adeno-associated Viral Vector Based Therapies Market in Europe for Gene Editing Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.2. Adeno-associated Viral Vector Based Therapies Market in Europe: Distribution by Therapeutic Area
26.2.1. Adeno-associated Viral Vector Based Therapies Market in Europe for Ophthalmic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.2.2. Adeno-associated Viral Vector Based Therapies Market in Europe for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.2.3. Adeno-associated Viral Vector Based Therapies Market in Europe for Musculoskeletal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.2.4. Adeno-associated Viral Vector Based Therapies Market in Europe for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC AND REST OF THE WORLD
27.1. Adeno-associated Viral Vector Based Therapies Market in Asia-Pacific and Rest of the World: Distribution by Type of Therapy
27.1.1. Adeno-associated Viral Vector Based Therapies Market in Asia-Pacific and Rest of the World for Gene Augmentation Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.1.2. Adeno-associated Viral Vector Based Therapies Market in Asia-Pacific and Rest of the World for Gene Regulation Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.1.3. Adeno-associated Viral Vector Based Therapies Market in Asia-Pacific and Rest of the World for Gene Editing Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.2. Adeno-associated Viral Vector Based Therapies Market in Asia-Pacific and Rest of the World: Distribution by Therapeutic Area
27.2.1. Adeno-associated Viral Vector Based Therapies Market in Asia-Pacific and Rest of the World for Ophthalmic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.2.2. Adeno-associated Viral Vector Based Therapies Market in Asia-Pacific and Rest of the World for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.2.3. Adeno-associated Viral Vector Based Therapies Market in Asia-Pacific and Rest of the World for Musculoskeletal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.2.4. Adeno-associated Viral Vector Based Therapies Market in Asia-Pacific and Rest of the World for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
28. ADENO-ASSOCIATED VIRAL VECTOR BASED THERAPIES MARKET: SALES FORECAST OF THERAPIES
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Commercialized Adeno-associated Viral Vector Based Therapies: Sales Forecast
28.3.1. Luxturna
28.3.1.1. Sales Forecast
28.3.1.2. Net Present Value
28.3.1.3. Value Creation Analysis
28.3.2. Hemgenix
28.3.2.1. Sales Forecast
28.3.2.2. Net Present Value
28.3.2.3. Value Creation Analysis
28.3.3. Zolgensma
28.3.3.1. Sales Forecast
28.3.3.2. Net Present Value
28.3.3.3. Value Creation Analysis
28.3.4. Roctavian
28.3.4.1. Sales Forecast
28.3.4.2. Net Present Value
28.3.4.3. Value Creation Analysis
28.3.5. Elevidys
28.3.5.1. Sales Forecast
28.3.5.2. Net Present Value
28.3.5.3. Value Creation Analysis
28.3.6. Upstaza
28.3.6.1. Sales Forecast
28.3.6.2. Net Present Value
28.3.6.3. Value Creation Analysis
28.3.7. BBM H901
28.3.7.1. Sales Forecast
28.3.7.2. Net Present Value
28.3.7.3. Value Creation Analysis
28.3.8. Itvisma
28.3.8.1. Sales Forecast
28.3.8.2. Net Present Value
28.3.8.3. Value Creation Analysis
28.4. Clinical Stage Adeno-Associated Vector Based Therapies: Sales Forecast
28.4.1. Giroctocogene fitelparvovec (SB-528 / PF-07055480)
28.4.1.1. Sales Forecast
28.4.2. RGX-314
28.4.2.1. Sales Forecast
28.4.3. RGX-121
28.4.3.1. Sales Forecast
28.4.4. DTx-401
28.4.4.1. Sales Forecast
28.4.5. DTx-301
28.4.5.1. Sales Forecast
28.4.6. ABO-102 (UX111)
28.4.6.1. Sales Forecast
28.4.7. LUMEVOQ
28.4.7.1. Sales Forecast
28.4.8. SPK-8011 (dirloctocogene samoparvovec)
28.4.8.1. Sales Forecast
28.4.9. AGTC 501 (rAAV2tYF-GRK1-RPGR)
28.4.9.1. Sales Forecast
28.4.10. NFS-01 (rAAV2-ND4)
28.4.10.1. Sales Forecast
28.4.11. 4D-150
28.4.11.1. Sales Forecast
28.4.12. Ixoberogene soroparvovec / Ixo-vec / ADVM-022
28.4.12.1. Sales Forecast
28.4.13. OAV-101
28.4.13.1. Sales Forecast
29. GLOBAL ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURING MARKET
29.1. Chapter Overview
29.2. Assumptions and Methodology
29.3. Global Adeno-associated Viral Vector Manufacturing Market: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
29.3.1. Scenario Analysis
29.3.1.1. Conservative Scenario
29.3.1.2. Optimistic Scenario
29.4. Key Market Segmentations
30. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURING MARKET, BY SCALE OF OPERATION
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Adeno-associated Viral Vector Manufacturing Market: Distribution by Scale of Operation
30.3.1. Adeno-associated Viral Vector Manufacturing Market for Commercial Scale: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
30.3.2. Adeno-associated Viral Vector Manufacturing Market for Clinical Scale: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
30.3.3. Adeno-associated Viral Vector Manufacturing Market for Preclinical Scale: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
30.4. Data Triangulation and Validation
31. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURING MARKET, BY TYPE OF MANUFACTURER
31.1. Chapter Overview
31.2. Assumptions and Methodology
31.3. Adeno-associated Viral Vector Manufacturing Market: Distribution by Type of Manufacturer
31.3.1. Adeno-associated Viral Vector Manufacturing Market for Contract Manufacturers: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
31.3.2. Adeno-associated Viral Vector Manufacturing Market for In-house Manufacturers: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
31.4. Data Triangulation and Validation
32. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURING MARKET, BY THERAPEUTIC AREA
32.1. Chapter Overview
32.2. Key Assumptions and Methodology
32.3. Adeno-associated Viral Vector Manufacturing Market: Distribution by Therapeutic Area
32.3.1. Adeno-associated Viral Vector Manufacturing Market for Oncological Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
32.3.2. Adeno-associated Viral Vector Manufacturing Market for Rare Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
32.3.3. Adeno-associated Viral Vector Manufacturing Market for Immunological Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
32.3.4. Adeno-associated Viral Vector Manufacturing Market for Neurological Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
32.3.5. Adeno-associated Viral Vector Manufacturing Market for Sensory Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
32.3.6. Adeno-associated Viral Vector Manufacturing Market for Metabolic Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
32.3.7. Adeno-associated Viral Vector Manufacturing Market for Blood Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
32.3.8. Adeno-associated Viral Vector Manufacturing Market for Musculoskeletal Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
32.3.9. Adeno-associated Viral Vector Manufacturing Market for Infectious Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
32.3.10. Adeno-associated Viral Vector Manufacturing Market for Ophthalmic Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
32.3.11. Adeno-associated Viral Vector Manufacturing Market for Other Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
32.4. Data Triangulation and Validation
33. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURING MARKET, BY GEOGRAPHICAL REGIONS
33.1. Chapter Overview
33.2. Key Assumptions and Methodology
33.3. Adeno-associated Viral Vector Manufacturing Market: Distribution by Geographical Regions
33.3.1. Adeno-associated Viral Vector Manufacturing Market in North America: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
33.3.2. Adeno-associated Viral Vector Manufacturing Market in Europe: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
33.3.3. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
33.3.4. Adeno-associated Viral Vector Manufacturing Market in Rest of the World: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
33.4. Market Dynamics Assessment
33.4.1. Penetration Growth (P-G) Matrix
33.5. Data Triangulation and Validation
34. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA
34.1. Adeno-associated Viral Vector Manufacturing Market in North America: Distribution by Scale of Operation
34.1.1. Adeno-associated Viral Vector Manufacturing Market in North America for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.1.2. Adeno-associated Viral Vector Manufacturing Market in North America for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.1.3. Adeno-associated Viral Vector Manufacturing Market in North America for Preclinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.2. Adeno-associated Viral Vector Manufacturing Market in North America: Distribution by Type of Manufacturer
34.2.1. Adeno-associated Viral Vector Manufacturing Market in North America for Contract Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.2.2. Adeno-associated Viral Vector Manufacturing Market in North America for In-house Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.3. Adeno-associated Viral Vector Manufacturing Market in North America: Distribution by Therapeutic Area
34.3.1. Adeno-associated Viral Vector Manufacturing Market in North America for Oncological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.3.2. Adeno-associated Viral Vector Manufacturing Market in North America for Rare Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.3.3. Adeno-associated Viral Vector Manufacturing Market in North America for Immunological Disorders, Historical Trends (since 2023) and Forecasted Estimates (Till 2035)
34.3.4. Adeno-associated Viral Vector Manufacturing Market in North America for Neurological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.3.5. Adeno-associated Viral Vector Manufacturing Market in North America for Sensory Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.3.6. Adeno-associated Viral Vector Manufacturing Market in North America for Metabolic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.3.7. Adeno-associated Viral Vector Manufacturing Market in North America for Blood Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.3.8. Adeno-associated Viral Vector Manufacturing Market in North America for Musculoskeletal Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.3.9. Adeno-associated Viral Vector Manufacturing Market in North America for Infectious Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.3.10. Adeno-associated Viral Vector Manufacturing Market in North America for Ophthalmic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.3.11. Adeno-associated Viral Vector Manufacturing Market in North America for Other Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35. MARKET OPPORTUNITY ANALYSIS: EUROPE
35.1. Adeno-associated Viral Vector Manufacturing Market in Europe: Distribution by Scale of Operation
35.1.1. Adeno-associated Viral Vector Manufacturing Market in Europe for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.1.2. Adeno-associated Viral Vector Manufacturing Market in Europe for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.1.3. Adeno-associated Viral Vector Manufacturing Market in Europe for Preclinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.2. Adeno-associated Viral Vector Manufacturing Market in Europe: Distribution by Type of Manufacturer
35.2.1. Adeno-associated Viral Vector Manufacturing Market in Europe for Contract Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.2.2. Adeno-associated Viral Vector Manufacturing Market in Europe for In-house Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.3. Adeno-associated Viral Vector Manufacturing Market in Europe: Distribution by Therapeutic Area
35.3.1. Adeno-associated Viral Vector Manufacturing Market in Europe for Oncological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.3.2. Adeno-associated Viral Vector Manufacturing Market in Europe for Rare Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.3.3. Adeno-associated Viral Vector Manufacturing Market in Europe for Immunological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.3.4. Adeno-associated Viral Vector Manufacturing Market in Europe for Neurological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.3.5. Adeno-associated Viral Vector Manufacturing Market in Europe for Sensory Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.3.6. Adeno-associated Viral Vector Manufacturing Market in Europe for Metabolic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.3.7. Adeno-associated Viral Vector Manufacturing Market in Europe for Blood Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.3.8. Adeno-associated Viral Vector Manufacturing Market in Europe for Musculoskeletal Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.3.9. Adeno-associated Viral Vector Manufacturing Market in Europe for Infectious Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.3.10. Adeno-associated Viral Vector Manufacturing Market in Europe for Ophthalmic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.3.11. Adeno-associated Viral Vector Manufacturing Market in Europe for Other Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC
36.1. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific: Distribution by Scale of Operation
36.1.1. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.1.2. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.1.3. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific for Preclinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.2. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific: Distribution by Type of Manufacturer
36.2.1. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific for Contract Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.2.2. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific for In-house Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.3. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific: Distribution by Therapeutic Area
36.3.1. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific for Oncological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.3.2. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific for Rare Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.3.3. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific for Immunological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.3.4. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific for Neurological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.3.5. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific for Sensory Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.3.6. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific for Metabolic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.3.7. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific for Blood Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.3.8. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific for Musculoskeletal Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.3.9. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific for Infectious Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.3.10. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific for Ophthalmic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.3.11. Adeno-associated Viral Vector Manufacturing Market in Asia-Pacific for Other Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
37. MARKET OPPORTUNITY ANALYSIS: REST OF THE WORLD
37.1. Adeno-associated Viral Vector Manufacturing Market in Rest of the World: Distribution by Scale of Operation
37.1.1. Adeno-associated Viral Vector Manufacturing Market in Rest of the World for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
37.1.2. Adeno-associated Viral Vector Manufacturing Market in Rest of the World for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
37.1.3. Adeno-associated Viral Vector Manufacturing Market in Rest of the World for Preclinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
37.2. Adeno-associated Viral Vector Manufacturing Market in Rest of the World: Distribution by Type of Manufacturer
37.2.1. Adeno-associated Viral Vector Manufacturing Market in Rest of the World for Contract Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
37.2.2. Adeno-associated Viral Vector Manufacturing Market in Rest of the World for In-house Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
37.3. Adeno-associated Viral Vector Manufacturing Market in Rest of the World: Distribution by Therapeutic Area
37.3.1. Adeno-associated Viral Vector Manufacturing Market in Rest of the World for Oncological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
37.3.2. Adeno-associated Viral Vector Manufacturing Market in Rest of the World for Rare Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
37.3.3. Adeno-associated Viral Vector Manufacturing Market in Rest of the World for Immunological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
37.3.4. Adeno-associated Viral Vector Manufacturing Market in Rest of the World for Neurological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
37.3.5. Adeno-associated Viral Vector Manufacturing Market in Rest of the World for Sensory Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
37.3.6. Adeno-associated Viral Vector Manufacturing Market in Rest of the World for Metabolic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
37.3.7. Adeno-associated Viral Vector Manufacturing Market in Rest of the World for Blood Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
37.3.8. Adeno-associated Viral Vector Manufacturing Market in Rest of the World for Musculoskeletal Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
37.3.9. Adeno-associated Viral Vector Manufacturing Market in Rest of the World for Infectious Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
37.3.10. Adeno-associated Viral Vector Manufacturing Market in Rest of the World for Ophthalmic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
37.3.11. Adeno-associated Viral Vector Manufacturing Market in Rest of the World for Other Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
38. CONCLUDING INSIGHTS
39. EXECUTIVE INSIGHTS
39.1. Chapter Overview
39.2. Company A
39.2.1. Company Snapshot
39.2.2. Interview Transcript: Chief Financial Officer
39.3. Company B
39.3.1. Company Snapshot
39.3.2. Interview Transcript: Professor of genetics and chief of division of cellular & molecular therapy Market Director
39.4. Company C
39.4.1. Company Snapshot
39.4.2. Interview Transcript: Professor
39.5. Company D
39.5.1. Company Snapshot
39.5.2. Interview Transcript: CEO
39.6. Company E
39.6.1. Company Snapshot
39.6.2. Interview Transcript: CEO
39.7. Company F
39.7.1. Company Snapshot
39.7.2. Interview Transcript: Business CEO
39.8. Company G
39.8.1. Company Snapshot
39.8.2. Interview Transcript: CEO
39.9. Company H
39.9.1. Company Snapshot
39.9.2. Interview Transcript: Group Vice President and Head of Global Medical Affairs
39.10. Company I
39.10.1. Company Snapshot
39.10.2. Interview Transcript: Vice President, Gene Therapy Research
39.11. Company J
39.11.1. Company Snapshot
39.11.2. Interview Transcript: Head of Downstream Process Development for Gene Therapy
39.12. Company K
39.12.1. Company Snapshot
39.12.2. Interview Transcript: Staff Research Engineer, Principal Scientist and Senior Principal Scientist
39.13. Company L
39.13.1. Company Snapshot
39.13.2. Interview Transcript: Senior Engineer II
39.14. Company M
39.14.1. Company Snapshot
39.14.2. Interview Transcript: Scientist
40. APPENDIX I: TABULATED DATA
41. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis (I/II)
Figure 5.4 Executive Summary: Market Forecast and Opportunity Analysis (II/II)
Figure 6.1 Classification of Vectors
Figure 6.2 Structure of Adeno-associated Viral Vector
Figure 6.3 Lytic Cycle of Adeno-associated Viral Vector
Figure 6.4 Lysogenic Cycle of Adeno-associated Viral Vector
Figure 7.1 Adeno-associated Viral Vector Based Therapies: Distribution by Stage of Development
Figure 7.2 Adeno-associated Viral Vector Based Therapies: Distribution by Type of Gene / Molecule Targeted
Figure 7.3 Adeno-associated Viral Vector Based Therapies: Distribution by Type of Therapy
Figure 7.4 Adeno-associated Viral Vector Based Therapies: Distribution by Route of Administration
Figure 7.5 Adeno-associated Viral Vector Based Therapies: Distribution by Therapeutic Area
Figure 7.6 Adeno-associated Viral Vector Based Therapies: Distribution by Special Designation Awarded
Figure 7.7 Adeno-associated Viral Vector Based Therapies: Distribution by Dose Frequency
Figure 7.8 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Year of Establishment
Figure 7.9 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Company Size
Figure 7.10 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Location of Headquarters (Region)
Figure 7.11 Most Active Developers: Distribution by Number of Therapies Developed
Figure 8.1 Adeno-associated Viral Vector Manufacturers: Distribution by Year of Establishment
Figure 8.2 Adeno-associated Viral Vector Manufacturers: Distribution by Company Size
Figure 8.3 Adeno-associated Viral Vector Manufacturers: Distribution by Location of Headquarters
Figure 8.4 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Product Manufactured
Figure 8.5 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Vector Manufactured
Figure 8.6 Adeno-associated Viral Vector Manufacturers: Distribution by Scale of Operation
Figure 8.7 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Manufacturer
Figure 8.8 Adeno-associated Viral Vector Manufacturers: Distribution by Application Area
Figure 8.9 Adeno-associated Viral Vector Manufacturers: Distribution by Location of Manufacturing Facility
Figure 9.1 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by Type of Vector Manufactured
Figure 9.2 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by Type of Viral Vector Manufactured
Figure 9.3 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by Scale of Operation
Figure 9.4 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by End-use
Figure 9.5 Adeno-associated Viral Vector Technology / Platform Providers: Distribution by Year of Establishment
Figure 9.6 Adeno-associated Viral Vector Technology Platform Providers: Distribution by Company Size
Figure 9.7 Adeno-associated Viral Vector Technology / Platform Providers: Distribution by Location of Headquarters
Figure 9.8 Most Active Players: Distribution by Number of Technologies / Platforms
Figure 10.1 Company Competitiveness Analysis: Overview of Peer Group I
Figure 10.2 Company Competitiveness Analysis: Overview of Peer Group II
Figure 10.3 Company Competitiveness Analysis: Overview of Peer Group III
Figure 10.4 Company Competitiveness Analysis: Adeno-associated Viral Vector Manufacturers Headquartered in North America (Peer Group I)
Figure 10.5 Company Competitiveness Analysis: Adeno-associated Viral Vector Manufacturers Headquartered in Europe (Peer Group II)
Figure 10.6 Company Competitiveness Analysis: Adeno-associated Viral Vector Manufacturers Headquartered in Asia-Pacific (Peer Group III)
Figure 11.1 Technology Competitiveness Analysis: Overview of Peer Group I
Figure 11.2 Technology Competitiveness Analysis: Overview of Peer Group II
Figure 11.3 Technology Competitiveness Analysis: Overview of Peer Group III
Figure 11.4 Technology Competitiveness Analysis: Adeno-associated Viral Vector Technologies / Platforms Provided by Companies Headquartered in North America (Peer Group I)
Figure 11.5 Technology Competitiveness Analysis: Adeno-associated Viral Vector Technologies / Platforms Provided by Companies Headquartered in Europe (Peer Group II)
Figure 11.6 Technology Competitiveness Analysis: Adeno-associated Viral Vector Technologies / Platforms Provided by Companies Headquartered in Asia-Pacific (Peer Group III)
Figure 12.1 Elevidys: Development Timeline
Figure 12.2 Hemgenix: Development Timeline
Figure 12.3 KEBILIDI: Development Timeline
Figure 12.4 Luxturna: Development Timeline
Figure 12.5 Roctavian: Development Timeline
Figure 12.6 Zolgensma: Development Timeline
Figure 12.7 Itvisma: Development Timeline
Figure 12.8 BBM-H901: Development Timeline
Figure 14.1 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, since 2020
Figure 14.2 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year, since 2020
Figure 14.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 14.4 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Phase
Figure 14.5 Clinical Trial Analysis: Distribution by Trial Status
Figure 14.6 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Status
Figure 14.7 Clinical Trial Analysis: Distribution of Patient Enrolled by Trial Status
Figure 14.8 Clinical Trial Analysis: Distribution by Target Patient Population
Figure 14.9 Clinical Trial Analysis: Distribution by Patient Gender
Figure 14.10 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 14.11 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used
Figure 14.12 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted
Figure 14.13 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 14.14 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 14.15 Most Active Industry Players: Distribution by Number of Clinical Trials Sponsored / Collaborated
Figure 14.16 Most Active Non-Industry Players: Distribution by Number of Clinical Trials Sponsored / Collaborated
Figure 14.17 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 14.18 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Figure 14.19 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Figure 14.20 Clinical Trial Analysis: Distribution of Clinical Trials by Geography, Trial Status and Trial Phase
Figure 15.1 Adeno-associated Viral Vector Manufacturers: Cumulative Year-wise Trend, Since 2021
Figure 15.2 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Partnership
Figure 15.3 Adeno-associated Viral Vector Manufacturers: Distribution by Year and Type of Partnership, Since 2021
Figure 15.4 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Partner
Figure 15.5 Adeno-associated Viral Vector Manufacturers: Distribution by Scale of Operation
Figure 15.6 Adeno-associated Viral Vector Manufacturers: Distribution by Therapeutic Area
Figure 15.7 Adeno-associated Viral Vector Manufacturers: Distribution by Application Area
Figure 15.8 Most Active Players: Distribution by Number of Partnerships
Figure 15.9 Adeno-associated Viral Vector Manufacturers: Local and International Agreements
Figure 15.10 Adeno-associated Viral Vector Manufacturers: Intracontinental and Intercontinental Agreements
Figure 16.1 Adeno-associated Viral Vector Based Therapy Developers: Cumulative Year-wise Trend, Since 2021
Figure 16.2 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Type of Partnership
Figure 16.3 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Year and Type of Partnership, Since 2021
Figure 16.4 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Type of Partner
Figure 16.5 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Therapeutic Area
Figure 16.6 Most Active Players: Distribution by Number of Partnerships
Figure 16.7 Adeno-associated Viral Vector Based Therapy Developers: Local and International Agreements
Figure 16.8 Adeno-associated Viral Vector Based Therapy Developers: Intracontinental and Intercontinental Agreements
Figure 17.1 Patent Analysis: Distribution by Type of Patent
Figure 17.2 Patent Analysis: Distribution by Patent Application Year, since Pre-2019
Figure 17.3 Patent Analysis: Distribution by Publication Year, since 2021
Figure 17.4 Patent Analysis: Distribution by Patent and Publication Year, since 2021
Figure 17.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 17.6 Patent Analysis: Distribution by CPC Symbols
Figure 17.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, since 2021
Figure 17.8 Leading Industry Players: Distribution by Number of Patents
Figure 17.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 17.10 Leading Patent Assignees: Distribution by Number of Patents
Figure 17.11 Patent Benchmarking Analysis: Distribution by Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 17.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 17.13 Patent Valuation: Distribution of Patents by Age
Figure 17.14 AAV Vector Market: Patent Valuation
Figure 18.1 Start-up Health Indexing: Distribution by Location of Headquarters
Figure 18.2 Start-up Health Indexing: Distribution by Pipeline Strength
Figure 18.3 Start-up Health Indexing: Distribution by Pipeline Maturity
Figure 18.4 Start-up Health Indexing: Distribution by Indication Diversity
Figure 18.5 Start-up Health Indexing: Distribution by Patent Strength
Figure 18.6 Start-up Health Indexing: Distribution by Partnership Activity
Figure 18.7 Start-up Health Indexing: Roots Analysis Perspective
Figure 18.8 Leading Start-ups: Spider Web Analysis
Figure 19.1 Outsourcing: Go / No Go Framework
Figure 19.2 Outsourcing: Go / No Go Framework for Adeno-associated Viral Vector Based Therapy Developers
Figure 19.3 Adeno-associated Viral Vector Based Therapy Developers: Benchmarking of Small Companies
Figure 19.4 Adeno-associated Viral Vector Based Therapy Developers: Benchmarking of Mid-sized Companies
Figure 19.5 Adeno-associated Viral Vector Based Therapy Developers: Benchmarking of Large Companies
Figure 21.1 Global Adeno-associated Viral Vector Based Therapies Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.2 Global Adeno-associated Viral Vector Based Therapies Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Figure 21.3 Adeno-associated Viral Vector Based Therapies Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Figure 22.1 Adeno-associated Viral Vector Based Therapies Market: Distribution by Type of Therapy
Figure 22.2. Adeno-associated Viral Vector Based Therapies Market for Gene Augmentation Therapies: Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.3. Adeno-associated Viral Vector Based Therapies Market for Gene Regulation Therapies: Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.4. Adeno-associated Viral Vector Based Therapies Market for Gene Editing Therapies: Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.1 Adeno-associated Viral Vector Based Therapies Market: Distribution by Therapeutic Area
Figure 23.2 Adeno-associated Viral Vector Based Therapies Market for Ophthalmic Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.3 Adeno-associated Viral Vector Based Therapies Market for Hematological Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.4 Adeno-associated Viral Vector Based Therapies Market for Musculoskeletal Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.5 Adeno-associated Viral Vector Based Therapies Market for Metabolic Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.1 Adeno-associated Viral Vector Based Therapies Market: Distribution by Geographical Regions
Figure 24.2 Adeno-associated Viral Vector Based Therapies Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.3 Adeno-associated Viral Vector Based Therapies Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.4 Adeno-associated Viral Vector Based Therapies Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.5 Penetration Growth (P-G) Matrix
Figure 28.1 Adeno-associated Viral Vector Based Therapies Market: Luxturna Sales Forecast, till 2035 (USD Million)
Figure 28.2 Adeno-associated Viral Vector Based Therapies Market: Hemgenix Sales Forecast, till 2035 (USD Million)
Figure 28.3 Adeno-associated Viral Vector Based Therapies Market: Zolgensma Sales Forecast, till 2035 (USD Million)
Figure 28.4 Adeno-associated Viral Vector Based Therapies Market: Roctavian Sales Forecast, till 2035 (USD Million)
Figure 28.5 Adeno-associated Viral Vector Based Therapies Market: Elevidys Sales Forecast, till 2035 (USD Million)
Figure 28.6 Adeno-associated Viral Vector Based Therapies Market: Upstaza Sales Forecast, till 2035 (USD Million)
Figure 28.7 Adeno-associated Viral Vector Based Therapies Market: BBM H901 Sales Forecast, till 2035 (USD Million)
Figure 28.8 Adeno-associated Viral Vector Based Therapies Market: Itvisma Sales Forecast, till 2035 (USD Million)
Figure 28.9 Adeno-associated Viral Vector Based Therapies Market: Giroctocogene fitelparvovec Sales Forecast, till 2035 (USD Million)
Figure 28.10 Adeno-associated Viral Vector Based Therapies Market: RGX-314 Sales Forecast, till 2028 (USD Million)
Figure 28.11 Adeno-associated Viral Vector Based Therapies Market: RGX-121 Sales Forecast, till 2028 (USD Million)
Figure 28.12 Adeno-associated Viral Vector Based Therapies Market: DTx-401 Sales Forecast, till 2035 (USD Million)
Figure 28.13 Adeno-associated Viral Vector Based Therapies Market: DTx-301 Sales Forecast, till 2035 (USD Million)
Figure 28.14 Adeno-associated Viral Vector Based Therapies Market: ABO-102 (UX111) Sales Forecast, till 2035 (USD Million)
Figure 28.15 Adeno-associated Viral Vector Based Therapies Market: LUMEVOQ Sales Forecast, till 2035 (USD Million)
Figure 28.16 Adeno-associated Viral Vector Based Therapies Market: SPK-8011 Sales Forecast, till 2035 (USD Million)
Figure 28.17 Adeno-associated Viral Vector Based Therapies Market: AGTC-501 Sales Forecast, till 2035 (USD Million)
Figure 28.18 Adeno-associated Viral Vector Based Therapies Market: NFS-01 Sales Forecast, till 2035 (USD Million)
Figure 28.19 Adeno-associated Viral Vector Based Therapies Market: 4D-150 Sales Forecast, till 2035 (USD Million)
Figure 28.20 Adeno-associated Viral Vector Based Therapies Market: Ixoberogene Soroparvovec Sales Forecast, till 2035 (USD Million)
Figure 28.21 Adeno-associated Viral Vector Based Therapies Market: OAV-101 Sales Forecast, till 2035 (USD Million)
Figure 29.1 Global Adeno-associated Viral Vector Based Manufacturing Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 29.2 Global Adeno-associated Viral Vector Based Manufacturing Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Figure 29.3 Global Adeno-associated Viral Vector Based Manufacturing Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Figure 30.1 Adeno-associated Viral Vector Based Manufacturing Market: Distribution by Scale of Operation
Figure 30.2 Adeno-associated Viral Vector Based Manufacturing Market for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 30.3 Adeno-associated Viral Vector Based Manufacturing Market for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 30.4 Adeno-associated Viral Vector Based Manufacturing Market for Preclinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.1 Adeno-associated Viral Vector Based Manufacturing Market: Distribution by Type of Manufacturer
Figure 31.2 Adeno-associated Viral Vector Based Manufacturing Market for Contract Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 31.3 Adeno-associated Viral Vector Based Manufacturing Market for In-house Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 32.1 Adeno-associated Viral Vector Based Manufacturing Market: Distribution by Therapeutic Area
Figure 32.2 Adeno-associated Viral Vector Based Manufacturing Market for Oncological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 32.3 Adeno-associated Viral Vector Based Manufacturing Market for Rare Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 32.4 Adeno-associated Viral Vector Based Manufacturing Market for Immunological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 32.5 Adeno-associated Viral Vector Based Manufacturing Market for Neurological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 32.6 Adeno-associated Viral Vector Based Manufacturing Market for Sensory Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 32.7 Adeno-associated Viral Vector Based Manufacturing Market for Metabolic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 32.8 Adeno-associated Viral Vector Based Manufacturing Market for Blood Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 32.9 Adeno-associated Viral Vector Based Manufacturing Market for Musculoskeletal Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 32.10 Adeno-associated Viral Vector Based Manufacturing Market for Infectious Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 32.11 Adeno-associated Viral Vector Based Manufacturing Market for Ophthalmic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 32.12 Adeno-associated Viral Vector Based Manufacturing Market for Other Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 33.1 Adeno-associated Viral Vector Based Manufacturing Market: Distribution by Geographical Regions
Figure 33.2 Adeno-associated Viral Vector Based Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 33.3 Adeno-associated Viral Vector Based Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 33.4 Adeno-associated Viral Vector Based Manufacturing Market in Asia-Pacific, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 33.5 Adeno-associated Viral Vector Based Manufacturing Market in Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 33.6 Penetration Growth (P-G) Matrix
Figure 38.1 Concluding Remarks: Adeno-Associated Viral Vector Based Therapies Market Landscape
Figure 38.2 Concluding Remarks: Adeno-Associated Viral Vector Based Manufacturers and Technologies / Platforms Landscape
Figure 38.3 Concluding Remarks: Clinical Trial Analysis
Figure 38.4 Concluding Remarks: Partnerships and Collaborations
Figure 38.5 Concluding Remarks: Patent Analysis
Figure 38.6 Concluding Remarks: Adeno-Associated Viral Vector-based Therapies Market Forecast
Figure 38.7 Concluding Remarks: Adeno-Associated Viral Vector Manufacturing Market Forecast
Table 7.1 Adeno-associated Viral Vector Based Therapy Market: Information on Developer, Stage of Development, Phase of Development and Type of Gene / Molecule Targeted
Table 7.2 Adeno-associated Viral Vector Based Therapy Market: Information on Developer, Type of Therapy, Route of Administration and Therapeutic Area
Table 7.3 Adeno-associated Viral Vector Based Therapy Market: Information on Developer, Special Designation Awarded and Dose Frequency
Table 7.4 List of Adeno-associated Viral Vector Based Therapy Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 8.1 Adeno-associated Viral Vector Manufacturers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 8.2 Adeno-associated Viral Vector Manufacturers: Information on Type of Product Manufactured and Type of Vector Manufactured
Table 8.3 Adeno-associated Viral Vector Manufacturers: Information on Scale of Operation and Type of Manufacturer
Table 8.4 Adeno-associated Viral Vector Manufacturers: Information on Application Area and Location of Manufacturing Facility
Table 9.1 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Information on Technology Provider, Type of Vector Manufactured and Type of Viral Vector Manufactured
Table 9.2 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Information on Scale of Operation and End-use
Table 9.3 Adeno-associated Viral Vector Manufacturing Technology / Platform Providers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 12.1 List of Marketed Adeno-associated Viral Vector Based Therapies Profiled
Table 12.2 Sarepta Therapeutics: Company Overview
Table 12.3 Elevidys: Current Status of Development
Table 12.4 uniQure: Company Overview
Table 12.5 Hemgenix: Current Status of Development
Table 12.6 PTC Therapeutics: Company Overview
Table 12.7 KEBILIDI: Current Status of Development
Table 12.8 Spark Therapeutics: Company Overview
Table 12.9 Luxturna: Current Status of Development
Table 12.10 BioMarin Pharmaceutical: Company Overview
Table 12.11 Roctavian: Current Status of Development
Table 12.12 Novartis: Company Overview
Table 12.13 Zolgensma: Current Status of Development
Table 12.14 Novartis: Company Overview
Table 12.15 Itvisma: Current Status of Development
Table 12.16 Belief Biomed: Company Overview
Table 12.17 BBM-H901: Current Status of Development
Table 13.1 AAV Vector Manufacturers: List of Companies Profiled
Table 13.2 Astellas Pharma: Company Overview
Table 13.3 Astellas Pharma: Vector Manufacturing Portfolio
Table 13.4 Charles River Laboratories: Company Overview
Table 13.5 Charles River Laboratories: Vector Manufacturing Portfolio
Table 13.6 Cytiva: Company Overview
Table 13.7 Cytiva: Vector Manufacturing Portfolio
Table 13.8 Lonza: Company Overview
Table 13.9 Lonza: Vector Manufacturing Portfolio
Table 13.10 Novartis Gene Therapies: Company Overview
Table 13.11 Novartis Gene Therapies: Vector Manufacturing Portfolio
Table 13.12 Sanofi: Company Overview
Table 13.13 Sanofi: Vector Manufacturing Portfolio
Table 13.14 Thermo Fisher Scientific: Company Overview
Table 13.15 Thermo Fisher Scientific: Vector Manufacturing Portfolio
Table 13.16 WuXi AppTec: Company Overview
Table 13.17 WuXi AppTec: Vector Manufacturing Portfolio
Table 16.1 Adeno-associated Viral Vector Based Therapy Developers: List of Partnerships and Collaborations, 2017-2026
Table 15.1 Adeno-associated Viral Vector Manufacturers: List of Partnerships and Collaborations, 2017-2026
Table 15.2 Adeno-associated Viral Vector Manufacturers: Information on Type of Partner and Scale of Operation
Table 15.3 Adeno-associated Viral Vector Manufacturers: Information on Therapeutic Area and Application Area
Table 16.2 Adeno-associated Viral Vector Based Therapy Developers: Information on Type of Partner and Therapeutic Area
Table 17.1 Patent Analysis: Top CPC Sections
Table 17.2 Patent Analysis: Top CPC Symbols
Table 17.3 Patent Analysis: Top CPC Codes
Table 17.4 Patent Analysis: Summary of Benchmarking Analysis
Table 17.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 17.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 17.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 18.1 List of Start-ups Developing Adeno-associated Viral Vectors
Table 28.1 Luxturna: Net Present Value (USD Million)
Table 28.2 Luxturna: Value Creation Analysis (USD Million)
Table 28.3 Hemgenix: Net Present Value (USD Million)
Table 28.4 Hemgenix: Value Creation Analysis (USD Million)
Table 28.5 Zolgensma: Net Present Value (USD Million)
Table 28.6 Zolgensma: Value Creation Analysis (USD Million)
Table 28.7 Roctavian: Net Present Value (USD Million)
Table 28.8 Roctavian: Value Creation Analysis (USD Million)
Table 28.9 Elevidys: Net Present Value (USD Million)
Table 28.10 Elevidys: Value Creation Analysis (USD Million)
Table 28.11 Upstaza: Net Present Value (USD Million)
Table 28.12 Upstaza: Value Creation Analysis (USD Million)
Table 28.13 BBM H901: Net Present Value (USD Million)
Table 28.14 BBM H901: Value Creation Analysis (USD Million)
Table 28.15 Itvisma: Net Present Value (USD Million)
Table 28.16 Itvisma: Value Creation Analysis (USD Million)
Table 39.1 Andelyn Bioscience: Organization Snapshot
Table 39.2 University of Florida: Organization Snapshot
Table 39.3 Boston College: Organization Snapshot
Table 40.1 Adeno-associated Viral Vector Based Therapies: Distribution by Status of Development
Table 40.2 Adeno-associated Viral Vector Based Therapies: Distribution by Type of Gene / Molecule Targeted
Table 40.3 Adeno-associated Viral Vector Based Therapies: Distribution by Type of Therapy
Table 40.4 Adeno-associated Viral Vector Based Therapies: Distribution by Route of Administration
Table 40.5 Adeno-associated Viral Vector Based Therapies: Distribution by Therapeutic Area
Table 40.6 Adeno-associated Viral Vector Based Therapies: Distribution by Special Designation Awarded
Table 40.7 Adeno-associated Viral Vector Based Therapies: Distribution by Dose Frequency
Table 40.8 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Year of Establishment
Table 40.9 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Company Size
Table 40.10 Adeno-associated Viral Vector Based Therapy Developers: Distribution by Location of Headquarters (Region)
Table 40.11 Most Active Developers: Distribution by Number of Therapies Developed
Table 40.12 Adeno-associated Viral Vector Manufacturers: Distribution by Year of Establishment
Table 40.13 Adeno-associated Viral Vector Manufacturers: Distribution by Company Size
Table 40.14 Adeno-associated Viral Vector Manufacturers: Distribution by Location of Headquarters (Region)
Table 40.15 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Product Manufactured
Table 40.16 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Vector Manufactured
Table 40.17 Adeno-associated Viral Vector Manufacturers: Distribution by Scale of Operation
Table 40.18 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Manufacturer
Table 40.19 Adeno-associated Viral Vector Manufacturers: Distribution by Application Area
Table 40.20 Adeno-associated Viral Vector Manufacturers: Distribution by Location of Manufacturing Facilities (Region)
Table 40.21 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by Type of Vector Manufactured
Table 40.22 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by Type of Viral Vector Manufactured
Table 40.23 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by Scale of Operation
Table 40.24 Adeno-associated Viral Vector Manufacturing Technologies / Platforms: Distribution by End-use
Table 40.25 Adeno-associated Viral Vector Technology / Platform Providers: Distribution by Year of Establishment
Table 40.26 Adeno-associated Viral Vector Technology / Platform Providers: Distribution by Company Size
Table 40.27 Adeno-associated Viral Vector Technology / Platform Providers: Distribution by Location of Headquarters (Region)
Table 40.28 Most Active Players: Distribution by Number of Technologies / Platforms
Table 40.29 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Registration Year Since 2020
Table 40.30 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year, since 2020
Table 40.31 Clinical Trial Analysis: Distribution by Trial Phase
Table 40.32 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patients Enrolled
Table 40.33 Clinical Trial Analysis: Distribution by Trial Status
Table 40.34 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Status
Table 40.35 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Trial Status
Table 40.36 Clinical Trial Analysis: Distribution by Target Patient Population
Table 40.37 Clinical Trial Analysis: Distribution by Patient Gender
Table 40.38 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 40.39 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used
Table 40.40 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted
Table 40.41 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 40.42 Clinical Trial Analysis: Distribution by Trial Purpose
Table 40.43 Most Active Industry Players: Distribution by Number of Clinical Trials Sponsored / Collaborated
Table 40.44 Most Active Non-Industry Players: Distribution by Number of Clinical Trials Sponsored / Collaborated
Table 40.45 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 40.46 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Table 40.47 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Table 40.48 Clinical Trial Analysis: Distribution of Clinical Trials by Geography, Trial Status and Trial Phase
Table 40.49 Adeno-associated Viral Vector Manufacturers: Cumulative Year-wise Trend, pre-2021-2026
Table 40.50 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Partnership
Table 40.51 Adeno-associated Viral Vector Manufacturers: Distribution by Year of Partnership and Type of Partnership, pre-2021-2026
Table 40.52 Adeno-associated Viral Vector Manufacturers: Distribution by Type of Partner
Table 40.53 Adeno-associated Viral Vector Manufacturers: Distribution by Scale of Operation
Table 40.54 Adeno-associated Viral Vector Manufacturers: Distribution by Therapeutic Area
Table 40.55 Adeno-associated Viral Vector Manufacturers: Distribution by Application Area
Table 40.56 Most Active Players: Distribution by Number of Partnerships
Table 40.57 Adeno-associated Viral Vector Manufacturers: Local and International Agreements
Table 40.58 Adeno-associated Viral Vector Manufacturers: Intracontinental and Intercontinental Agreements
Table 40.59 Adeno-associated Viral Vector based Therapy Developers: Cumulative Year-wise Trend, Pre-2021-2026
Table 40.60 Adeno-associated Viral Vector based Therapy Developers: Distribution by Type of Partnership
Table 40.61 Adeno-associated Viral Vector based Therapy Developers: Distribution by Year and Type of Partnership, Pre-2021-2026
Table 40.62 Adeno-associated Viral Vector based Therapy Developers: Distribution by Type of Partner
Table 40.63 Adeno-associated Viral Vector based Therapy Developers: Distribution by Therapeutic Area
Table 40.64 Most Active Players: Distribution by Number of Partnerships
Table 40.65 Adeno-associated Viral Vector based Therapy Developers: Local and International Agreements
Table 40.66 Adeno-associated Viral Vector based Therapy Developers: Intracontinental and Intercontinental Agreements
Table 40.67 Patent Analysis: Distribution by Type of Patent
Table 40.68 Patent Analysis: Distribution by Patent Application Year, since Pre-2019-2025
Table 40.69 Patent Analysis: Distribution by Publication Year, since 2021
Table 40.70 Patent Analysis: Type of Patent and Publication Year
Table 40.71 Patent Analysis: Distribution by Patent Jurisdiction
Table 40.72 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, since 2021
Table 40.73 Leading Industry Players: Distribution by Number of Patents
Table 40.74 Leading Non-Industry Players: Distribution by Number of Patents
Table 40.75 Leading Patent Assignees: Distribution by Number of Patents
Table 40.76 Patent Valuation: Distribution of Patents by Age
Table 40.77 Adeno-associated Viral Vectors: Patent Valuation
Table 40.78 Start-up Health Indexing: Distribution by Location of Headquarters
Table 40.79 Start-up Health Indexing: Distribution by Pipeline Strength
Table 40.80 Start-up Health Indexing: Distribution by Pipeline Maturity
Table 40.81 Start-up Health Indexing: Distribution by Indication Diversity
Table 40.82 Analysis of Start-ups: Distribution by Patent Strength
Table 40.83 Start-up Health Indexing: Distribution by Partnership Activity
Table 40.84 Global Adeno-associated Viral Vector Based Therapies Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 40.85 Global Adeno-associated Viral Vector Based Therapies Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Million)
Table 40.86 Global Adeno-associated Viral Vector Based Therapies Market Forecasted Estimates (till 2035) Optimistic Scenario (USD Million)
Table 40.87 Adeno-associated Viral Vector Based Therapies Market: Distribution by Type of Therapy
Table 40.88 Adeno-associated Viral Vector Based Therapies Market for Gene Augmentation Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.89 Adeno-associated Viral Vector Based Therapies Market for Gene Regulation Therapies, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.90 Adeno-associated Viral Vector Based Therapies Market for Gene Editing Therapies, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.91 Adeno-associated Viral Vector Based Therapies Market: Distribution by Therapeutic Area
Table 40.92 Adeno-associated Viral Vector Based Therapies Market for Ophthalmic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.93 Adeno-associated Viral Vector Based Therapies Market for Hematological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.94 Adeno-associated Viral Vector Based Therapies Market for Musculoskeletal Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.95 Adeno-associated Viral Vector Based Therapies Market for Metabolic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.96 Adeno-associated Viral Vector Based Therapies Market: Distribution by Geographical Regions
Table 40.97 Adeno-associated Viral Vector Based Therapies Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.98 Adeno-associated Viral Vector Based Therapies Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.99 Adeno-associated Viral Vector Based Therapies Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.100 Adeno-associated Viral Vector Based Therapeutics Market: Luxturna Sales Forecast, till 2035 (USD Million)
Table 40.101 Adeno-associated Viral Vector Based Therapeutics Market: Hemgenix Sales Forecast, till 2035 (USD Million)
Table 40.102 Adeno-associated Viral Vector Based Therapeutics Market: Zolgensma Sales Forecast, till 2035 (USD Million)
Table 40.103 Adeno-associated Viral Vector Based Therapeutics Market: Roctavian Sales Forecast, till 2035 (USD Million)
Table 40.104 Adeno-associated Viral Vector Based Therapeutics Market: Elevidys Sales Forecast, till 2035 (USD Million)
Table 40.105 Adeno-associated Viral Vector Based Therapeutics Market: Upstaza Sales Forecast, till 2035 (USD Million)
Table 40.106 Adeno-associated Viral Vector Based Therapeutics Market: BBM-H901 Sales Forecast, till 2035 (USD Million)
Table 40.107 Adeno-associated Viral Vector Based Therapeutics Market: Itvisma Sales Forecast, till 2035 (USD Million)
Table 40.108 Adeno-associated Viral Vector Based Therapeutics Market: Giroctocogene fitelparvovec Sales Forecast, till 2035 (USD Million)
Table 40.109 Adeno-associated Viral Vector Based Therapeutics Market: RGX-314 Sales Forecast, till 2025 (USD Million)
Table 40.110 Adeno-associated Viral Vector Based Therapeutics Market: RGX-121 Sales Forecast, till 2035 (USD Million)
Table 40.111 Adeno-associated Viral Vector Based Therapeutics Market: DTx-401Sales Forecast, till 2035 (USD Million)
Table 40.112 Adeno-associated Viral Vector Based Therapeutics Market: DTx-301Sales Forecast, till 2035 (USD Million)
Table 40.113 Adeno-associated Viral Vector Based Therapeutics Market: ABO-102 (UX111) Sales Forecast, till 2035 (USD Million)
Table 40.114 Adeno-associated Viral Vector Based Therapeutics Market: LUMEVOQ Sales Forecast, till 2035 (USD Million)
Table 40.115 Adeno-associated Viral Vector Based Therapeutics Market: SPK-8011 Sales Forecast, till 2035 (USD Million)
Table 40.116 Adeno-associated Viral Vector Based Therapeutics Market: AGTC 501 Sales Forecast, till 2035 (USD Million)
Table 40.117 Adeno-associated Viral Vector Based Therapeutics Market: NFS-01 Sales Forecast, till 2035 (USD Million)
Table 40.118 Adeno-associated Viral Vector Based Therapeutics Market: 4D-150 Sales Forecast, till 2035 (USD Million)
Table 40.119 Adeno-associated Viral Vector Based Therapeutics Market: Ixoberogene Soroparvovec Sales Forecast, till 2035 (USD Million)
Table 40.120 Adeno-associated Viral Vector Based Therapeutics Market: OAV-101 Sales Forecast, till 2035 (USD Million)
Table 40.121 Global Adeno-associated Viral Vector Based Manufacturing Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 40.122 Global Adeno-associated Viral Vector Based Manufacturing Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Million)
Table 40.123 Global Adeno-associated Viral Vector Based Manufacturing Market, Forecasted Estimates (till 2035) Optimistic Scenario (USD Million)
Table 40.124 Adeno-associated Viral Vector Based Manufacturing Market: Distribution by Scale of Operation
Table 40.125 Adeno-associated Viral Vector Based Manufacturing Market for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.126 Adeno-associated Viral Vector Based Manufacturing Market for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.127 Adeno-associated Viral Vector Based Manufacturing Market for Preclinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.128 Adeno-associated Viral Vector Based Manufacturing Market: Distribution by Type of Manufacturer
Table 40.129 Adeno-associated Viral Vector Based Manufacturing Market for Contract Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.130 Adeno-associated Viral Vector Based Manufacturing Market for In-house Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.131 Adeno-associated Viral Vector Based Manufacturing Market: Distribution by Therapeutic Area
Table 40.132 Adeno-associated Viral Vector Based Manufacturing Market for Oncological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.133 Adeno-associated Viral Vector Based Manufacturing Market for Rare Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.134 Adeno-associated Viral Vector Based Manufacturing Market for Immunological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.135 Adeno-associated Viral Vector Based Manufacturing Market for Neurological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.136 Adeno-associated Viral Vector Based Manufacturing Market for Sensory Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.137 Adeno-associated Viral Vector Based Manufacturing Market for Metabolic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.138 Adeno-associated Viral Vector Based Manufacturing Market for Blood Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.139 Adeno-associated Viral Vector Based Manufacturing Market for Musculoskeletal Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.140 Adeno-associated Viral Vector Based Manufacturing Market for Infectious Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.141 Adeno-associated Viral Vector Based Manufacturing Market for Ophthalmic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.142 Adeno-associated Viral Vector Based Manufacturing Market for Other Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.143 Adeno-associated Viral Vector Based Manufacturing Market: Distribution by Geographical Regions
Table 40.144 Adeno-associated Viral Vector Based Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.145 Adeno-associated Viral Vector Based Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.146 Adeno-associated Viral Vector Based Manufacturing Market in Asia-Pacific, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 40.147 Adeno-associated Viral Vector Based Manufacturing Market in Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)